Cellular basis for triggered ventricular arrhythmias that occur in the setting of compensated hypertrophy and heart failure: considerations for diagnosis and treatment

Journal of Electrocardiology

Volumn 40, Issue 6 SUPPL. 1, 2007, Pages

  Antoons, Gudrun ^a   Oros, Avram ^a   Bito, Virginie ^b   Sipido, Karin R ^b   Vos, Marc A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Afterdepolarizations; Antiarrhythmic therapy; Beat to beat variability of repolarization; Remodeling; SR Ca2+ release

Indexed keywords

4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; ANTIARRHYTHMIC AGENT; CALCIUM; CALMODULIN INHIBITOR; CLOFILIUM; FLUNARIZINE; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; NISOLDIPINE; OUABAIN; RANOLAZINE;

ARTICLE; CALCIUM TRANSPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG MECHANISM; HEART DEPOLARIZATION; HEART FAILURE; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; LONG QT SYNDROME; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; TORSADE DES POINTES; TREATMENT RESPONSE;

ANTI-ARRHYTHMIA AGENTS; CARDIAC OUTPUT, LOW; CARDIOMEGALY; HEART CONDUCTION SYSTEM; HUMANS; MODELS, CARDIOVASCULAR; VENTRICULAR FIBRILLATION;

EID: 35748964999     PISSN: 00220736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jelectrocard.2007.05.022     Document Type: Article

References (71)

1. Zipes D.P., and Wellens H.J. Sudden cardiac death. Circulation 98 (1998) 2334
2. Anderson K.P., Walker R., Urie P., Ershler P.R., Lux R.L., and Karwandee S.V. Myocardial electrical propagation in patients with idiopathic dilated cardiomyopathy. J Clin Invest 92 (1993) 122
3. Pogwizd S.M., Hoyt R.H., Saffitz J.E., Corr P.B., Cox J.L., and Cain M.E. Reentrant and focal mechanisms underlying ventricular tachycardia in the human heart. Circulation 86 (1992) 1872
4. Pogwizd S.M., McKenzie J.P., and Cain M.E. Mechanisms underlying spontaneous and induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. Circulation 98 (1998) 2404
5. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 79 (1999) 215
6. Thomsen M.B., Verduyn S.C., Stengl M., et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 110 (2004) 2453
7. 2+ current. Circ Res 64 (1989) 977
8. Boutjdir M., Restivo M., Wei Y., Stergiopoulos K., and el-Sherif N. Early afterdepolarization formation in cardiac myocytes: analysis of phase plane patterns, action potential, and membrane currents. J Cardiovasc Electrophysiol 5 (1994) 609
9. 2+ release causes myocyte depolarization. Underlying mechanism and threshold for triggered action potentials. Circ Res 87 (2000) 774
10. Verkerk A.O., Veldkamp M.W., Baartscheer A., et al. Ionic mechanism of delayed afterdepolarizations in ventricular cells isolated from human end-stage failing hearts. Circulation 104 (2001) 2728
11. R4496C knock-in mouse model. Circ Res 99 (2006) 292
12. Marx S.O., Reiken S., Hisamatsu Y., et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101 (2000) 365
13. Jungschleger J.G.M., van der Hulst F., Leunissen J.D.M., et al. No dominant role for re-entry in the perpetuation of drug induced Torsade de Pointes arrhythmias in the CAVB-dog. Pacing Clin Electrophysiol 25 (2002) 627
14. de Groot S.H., Schoenmakers M., Molenschot M.M., Leunissen J.D., Wellens H.J., and Vos M.A. Contractile adaptations preserving cardiac output predispose the hypertrophied canine heart to delayed afterdepolarization-dependent ventricular arrhythmias. Circulation 102 (2000) 2145
15. Vos M.A., de Groot S.H., Verduyn S.C., et al. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation 98 (1998) 1125
16. Thomsen M.B., Oros A., Schoenmakers M., et al. Proarrhythmic electrical remodelling is associated with increased beat-to-beat variability of repolarisation. Cardiovasc Res 73 (2007) 521
17. Volders P.G., Sipido K.R., Vos M.A., Kulcsar A., Verduyn S.C., and Wellens H.J. Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes. Circulation 98 (1998) 1136
18. 2+ release and Na/Ca exchange activity in hypertrophied canine ventricular myocytes: potential link between contractile adaptation and arrhythmogenesis. Circulation 102 (2000) 2137
19. + currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. Circulation 100 (1999) 2455
20. + concentration and altered Na/K pump activity in hypertrophied canine ventricular cells. Cardiovasc Res 57 (2003) 1035
21. Volders P.G., Vos M.A., Szabo B., et al. Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts. Cardiovasc Res 46 (2000) 376
22. 2+ release in hypertrophied cardiac myocytes from dogs with chronic atrioventricular block. J Physiol 579 (2007) 147
23. Stengl M., Ramakers C., Donker D.W., et al. Temporal patterns of electrical remodeling in canine ventricular hypertrophy: focus on IKs downregulation and blunted beta-adrenergic activation. Cardiovasc Res 72 (2006) 90
24. Roden D.M. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 21 (1998) 1029
25. 2+ release and repolarization lability in myocytes from the dog with chronic atrioventricular block (cAVB). Biophys J 88 (2005) 298A
26. Thomsen M.B., Truin M., van Opstal J.M., et al. Sudden cardiac death in dogs with remodeled hearts is associated with larger beat-to-beat variability of repolarization. Basic Res Cardiol 100 (2005) 279
27. Hinterseer M., Beckmann B., Thomsen M.B., et al. Beat-to-beat variability of QT intervals is increased in drug induced and congenital long QT syndromes. Heart Rhythm 3 (2006) S269
28. Armoundas A.A., Wu R., Juang G., Marban E., and Tomaselli G.F. Electrical and structural remodeling of the failing ventricle. Pharmacol Ther 92 (2001) 213
29. Valdivia C.R., Chu W.W., Pu J., et al. Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. J Mol Cell Cardiol 38 (2005) 475
30. Veldkamp M.W., Verkerk A.O., van Ginneken A.C., et al. Norepinephrine induces action potential prolongation and early afterdepolarizations in ventricular myocytes isolated from human end-stage failing hearts. Eur Heart J 22 (2001) 955
31. Baartscheer A., Schumacher C.A., Belterman C.N., Coronel R., and Fiolet J.W. SR calcium handling and calcium after-transients in a rabbit model of heart failure. Cardiovasc Res 58 (2003) 99
32. Pogwizd S.M., Schlotthauer K., Li L., Yuan W., and Bers D.M. Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res 88 (2001) 1159
33. Hasenfuss G., and Pieske B. Calcium cycling in congestive heart failure. J Mol Cell Cardiol 34 (2002) 951
34. 2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res 94 (2004) e61
35. Trafford A.W., Sibbring G.C., Diaz M.E., and Eisner D.A. The effects of low concentrations of caffeine on spontaneous Ca release in isolated rat ventricular myocytes. Cell Calcium 28 (2000) 269
36. Venetucci L.A., Trafford A.W., and Eisner D.A. Increasing ryanodine receptor open probability alone does not produce arrhythmogenic calcium waves: threshold sarcoplasmic reticulum calcium content is required. Circ Res 100 (2007) 105
37. 2+-dependent reduction of IK1 in rat ventricular cells: a novel paradigm for arrhythmia in heart failure?. Cardiovasc Res 68 (2005) 204
38. Tytgat J., Pauwels P.J., Vereecke J., and Carmeliet E. Flunarizine inhibits a high-threshold inactivating calcium channel (N-type) in isolated hippocampal neurons. Brain Res 549 (1991) 112
39. 2+ channel blockade by flunarizine in ventricular myocytes of the guinea-pig. Eur J Pharmacol 296 (1996) 189
40. Dubin A.E., Nasser N., Rohrbacher J., et al. Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp. J Biomol Screen 10 (2005) 168
41. Trepakova E.S., Dech S.J., and Salata J.J. Flunarizine is a highly potent inhibitor of cardiac hERG potassium current. J Cardiovasc Pharmacol 47 (2006) 211
42. 2+ overload. J Pharmacol Exp Ther 279 (1996) 231
43. Verduyn S.C., Vos M.A., Gorgels A.P., van der Zande J., Leunissen J.D., and Wellens H.J. The effect of flunarizine and ryanodine on acquired torsades de pointes arrhythmias in the intact canine heart. J Cardiovasc Electrophysiol 6 (1995) 189
44. Jonkman F.A., Boddeke H.W., and van Zwieten P.A. Protective activity of calcium entry blockers against ouabain intoxication in anesthetized guinea pigs. J Cardiovasc Pharmacol 8 (1986) 1009
45. Park J., Danilo P., and Rosen M. Effects of flunarizine on impulse initiation in canine Purkinje fibers. J Cardiovasc Electrophysiol 3 (1992) 306
46. Vos M.A., Gorgels A.P., Leunissen J.D., and Wellens H.J. Flunarizine allows differentiation between mechanisms of arrhythmias in the intact heart. Circulation 81 (1990) 343
47. 2+ transient amplitude in adult ventricular myocytes. Circ Res 98 (2006) 1299
48. Kaneko N. New 1,4-benzothiapezine derivative, K201, demonstrates cardioprotective effects against sudden cardiac death and intracellular blocking action. Drug Dev Res 33 (1994) 429
49. Kohno M., Yano M., Kobayashi S., et al. A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure. Am J Physiol 284 (2003) H1035
50. Wehrens X.H., Lehnart S.E., Reiken S., et al. Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. Proc Natl Acad Sci 102 (2005) 9607
51. Yano M., Kobayashi S., Kohno M., et al. FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 107 (2003) 477
52. Kimura J., Kawahara M., Sakai E., Yatabe J., and Nakanishi H. Effects of a novel cardioprotective drug, JTV-519, on membrane currents of guinea pig ventricular myocytes. Jpn J Pharmacol 79 (1999) 275
53. Wehrens X.H., Lehnart S.E., Reiken S.R., et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 304 (2004) 292
54. Lehnart S.E., Wehrens X.H., Laitinen P.J., et al. Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak. Circulation 109 (2004) 3208
55. Hasumi H., Matsuda R., Shimamoto K., Hata Y., and Kaneko N. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization. Eur J Pharmacol 555 (2007) 54
56. Dzhura I., Wu Y., Colbran R.J., Balser J.R., and Anderson M.E. Calmodulin kinase determines calcium-dependent facilitation of L-type calcium channels. Nat Cell Biol 2 (2000) 173
57. Curran J., Hinton M.J., Rios E., Bers D.M., and Shannon T.R. Beta-adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase. Circ Res 100 (2007) 391
58. + channels. J Clin Invest 116 (2006) 3127
59. + currents. Circ Res 99 (2006) 1092
60. Mazur A., Roden D.M., and Anderson M.E. Systemic administration of calmodulin antagonist W-7 or protein kinase A inhibitor H-8 prevents torsade de pointes in rabbits. Circulation 100 (1999) 2437
61. Lu H.R., Vlaminckx E., Van de Water A., and Gallacher D.J. Calmodulin antagonist W-7 prevents sparfloxacin-induced early afterdepolarizations (EADs) in isolated rabbit purkinje fibers: importance of beat-to-beat instability of the repolarization. J Cardiovasc Electrophysiol 17 (2006) 415
62. Gbadebo T.D., Trimble R.W., Khoo M.S., Temple J., Roden D.M., and Anderson M.E. Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes. Circulation 105 (2002) 770
63. Khoo M.S., Li J., Singh M.V., et al. Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy. Circulation 114 (2006) 1352
64. Kirchhof P., Fabritz L., Kilic A., Begrow F., Breithardt G., and Kuhn M. Ventricular arrhythmias, increased cardiac calmodulin kinase II expression, and altered repolarization kinetics in ANP receptor deficient mice. J Mol Cell Cardiol 36 (2004) 691
65. Wu Y., Temple J., Zhang R., et al. Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation 106 (2002) 1288
66. Zhang R., Khoo M.S., Wu Y., et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 11 (2005) 409
67. Antzelevitch C., Belardinelli L., Zygmunt A.C., et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110 (2004) 904
68. Schram G., Zhang L., Derakhchan K., Ehrlich J.R., Belardinelli L., and Nattel S. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol 142 (2004) 1300
69. Fredj S., Sampson K.J., Liu H., and Kass R.S. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol 148 (2006) 16
70. Wu L., Shryock J.C., Song Y., Li Y., Antzelevitch C., and Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther 310 (2004) 599
71. Undrovinas A.I., Belardinelli L., Undrovinas N.A., and Sabbah H.N. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 17 Suppl 1 (2006) S169